MannKind Announces Settlement of Convertible Senior Notes
MannKind (Nasdaq: MNKD) announced settlement of the remaining $36.3 million aggregate principal amount of 2.50% convertible senior notes, all tendered for conversion prior to the March 1, 2026 maturity.
Rhea-AI Summary
MannKind (Nasdaq: MNKD) announced settlement of the remaining $36.3 million aggregate principal amount of 2.50% convertible senior notes, all tendered for conversion prior to the March 1, 2026 maturity.
The company settled on March 4, 2026 using $35.5 million in cash and issuance of 569,023 shares of common stock.
Positive
- Convertible notes fully settled on March 4, 2026
- Cash component of settlement was $35.5 million
Negative
- Issuance of 569,023 shares increased outstanding shares, causing shareholder dilution
- Company used $35.5 million cash to settle notes, reducing cash resources
Details
News Market Reaction – MNKD
In the Mar 6 session, MNKD declined 7.77%, reflecting a notable negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Convertible notes principal
- $36.3M
- Remaining 2.50% convertible senior notes tendered before March 1, 2026 maturity
- Coupon rate
- 2.50%
- Interest rate on convertible senior notes settled
- Cash portion
- $35.5M
- Cash used to settle remaining convertible notes on March 4, 2026
- Shares issued
- 569,023 shares
- MannKind common stock issued as part of note settlement
- Maturity date
- March 1, 2026
- Scheduled maturity for 2.50% convertible senior notes
- Settlement date
- March 4, 2026
- Date remaining convertible notes were settled
Historical Context
-
Participation in two Miami investor conferences with CEO and CFO presentations.
-
Q4 and 2025 revenue growth with business update including acquisitions and PDUFA dates.
-
CEO presentation and business updates at Oppenheimer healthcare conference.
-
Announcement of timing and webcast details for Q4 and full-year 2025 results.
-
First patient enrolled in INHALE-1ST pediatric Afrezza study and PDUFA reminder.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
convertible senior notes financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) today announced the settlement of the remaining
About MannKind
MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, we develop and commercialize treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.
With deep expertise in drug-device combinations, MannKind aims to deliver therapies designed to fit seamlessly into daily life.
Learn more at mannkindcorp.com.
MANNKIND is a registered trademark of MannKind Corporation.

MannKind Contacts: Investor Relations Kate Miranda (617) 921-5461 Email: ir@mnkd.com Media Relations Christie Iacangelo (818) 292-3500 Email: media@mnkd.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.